Cargando…

Application of Novel Drugs for Corneal Cell Regeneration

Corneal transplantation has been the only treatment method for corneal blindness, which is the major cause of reversible blindness. However, despite the advancement of surgical techniques for corneal transplantation, demand for the surgery can never be met due to a global shortage of donor cornea. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sang Beom, Liu, Yu-Chi, Mohamed-Noriega, Karim, Mehta, Jodhbir S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954904/
https://www.ncbi.nlm.nih.gov/pubmed/29854423
http://dx.doi.org/10.1155/2018/1215868
_version_ 1783323611353841664
author Han, Sang Beom
Liu, Yu-Chi
Mohamed-Noriega, Karim
Mehta, Jodhbir S.
author_facet Han, Sang Beom
Liu, Yu-Chi
Mohamed-Noriega, Karim
Mehta, Jodhbir S.
author_sort Han, Sang Beom
collection PubMed
description Corneal transplantation has been the only treatment method for corneal blindness, which is the major cause of reversible blindness. However, despite the advancement of surgical techniques for corneal transplantation, demand for the surgery can never be met due to a global shortage of donor cornea. The development of bioengineering and pharmaceutical technology provided us with novel drugs and biomaterials that can be used for innovative treatment methods for corneal diseases. In this review, the authors will discuss the efficacy and safety of pharmacologic therapies, such as Rho-kinase (ROCK) inhibitors, blood-derived products, growth factors, and regenerating agent on corneal cell regeneration. The promising results of these agents suggest that these can be viable options for corneal reconstruction and visual rehabilitation.
format Online
Article
Text
id pubmed-5954904
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59549042018-05-31 Application of Novel Drugs for Corneal Cell Regeneration Han, Sang Beom Liu, Yu-Chi Mohamed-Noriega, Karim Mehta, Jodhbir S. J Ophthalmol Review Article Corneal transplantation has been the only treatment method for corneal blindness, which is the major cause of reversible blindness. However, despite the advancement of surgical techniques for corneal transplantation, demand for the surgery can never be met due to a global shortage of donor cornea. The development of bioengineering and pharmaceutical technology provided us with novel drugs and biomaterials that can be used for innovative treatment methods for corneal diseases. In this review, the authors will discuss the efficacy and safety of pharmacologic therapies, such as Rho-kinase (ROCK) inhibitors, blood-derived products, growth factors, and regenerating agent on corneal cell regeneration. The promising results of these agents suggest that these can be viable options for corneal reconstruction and visual rehabilitation. Hindawi 2018-05-02 /pmc/articles/PMC5954904/ /pubmed/29854423 http://dx.doi.org/10.1155/2018/1215868 Text en Copyright © 2018 Sang Beom Han et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Han, Sang Beom
Liu, Yu-Chi
Mohamed-Noriega, Karim
Mehta, Jodhbir S.
Application of Novel Drugs for Corneal Cell Regeneration
title Application of Novel Drugs for Corneal Cell Regeneration
title_full Application of Novel Drugs for Corneal Cell Regeneration
title_fullStr Application of Novel Drugs for Corneal Cell Regeneration
title_full_unstemmed Application of Novel Drugs for Corneal Cell Regeneration
title_short Application of Novel Drugs for Corneal Cell Regeneration
title_sort application of novel drugs for corneal cell regeneration
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954904/
https://www.ncbi.nlm.nih.gov/pubmed/29854423
http://dx.doi.org/10.1155/2018/1215868
work_keys_str_mv AT hansangbeom applicationofnoveldrugsforcornealcellregeneration
AT liuyuchi applicationofnoveldrugsforcornealcellregeneration
AT mohamednoriegakarim applicationofnoveldrugsforcornealcellregeneration
AT mehtajodhbirs applicationofnoveldrugsforcornealcellregeneration